Shares of Cardinal Health surged 7.6% to $255.16 on August 11, sharply outperforming flat broader indexes after the drug distributor delivered a fourth-quarter earnings blowout and aggressive forward guidance. The question now: how much of today's beat reflects durable business improvement versus one-time tailwinds.
A 20% Earnings Beat Powered Partly by a Tariff Windfall
Cardinal Health reported Q4 fiscal 2026 revenue of $63.7 billion, up 6% year over year, with non-GAAP EPS rising 40% to $2.91 — but that figure included a one-time $100 million tariff refund booked in its medical-products division.
Revenue fell short of the $65.11 billion consensus, yet EPS came in 20.2% above analyst estimates. Strip out the tariff benefit and the beat narrows meaningfully, a nuance investors will pressure management to quantify on the call.
Specialty Drugs Are Becoming the Real Profit Engine
For the full fiscal year, the Pharmaceutical and Specialty Solutions segment posted $2.8 billion in profit, up 23%. Quarterly pharma profit hit $645 million, rising 21%, driven by booming demand for specialty medications — high-cost drugs for conditions like cancer and autoimmune disorders that carry wider margins than generic distribution. Management previously said specialty revenues were growing at more than 20% and expected to exceed $50 billion in fiscal 2026 , signaling this isn't a one-quarter phenomenon but a structural business shift toward higher-value products.
Management Is Betting Big on Buybacks to Reward Shareholders
Cardinal Health repurchased $1.4 billion of shares in fiscal 2026 and obtained an additional $5.0 billion repurchase authorization, bringing total buyback capacity to $6.4 billion.
Over five years, the company has shrunk its share count by nearly 20% , amplifying EPS growth even when revenue growth is modest. That financial engineering works — until it doesn't, especially if cash flow contracts.
Guidance Looks Strong, But Cash Flow Is Set to Drop
For fiscal 2027, Cardinal Health guided non-GAAP EPS to $12.40–$12.60, implying 13%–15% growth over adjusted fiscal 2026.
That growth rate sits above its long-term earnings-per-share guidance , giving bulls confidence. But a quiet detail tempers the optimism: fiscal 2027 free cash flow is projected at $3.5–$4.0 billion, a notable step-down from this year's $5.0 billion . Less cash means less room to simultaneously fund buybacks, acquisitions, and the specialty platform investments that are driving the profit story. Investors should watch whether Cardinal can sustain its capital-return ambitions without stretching the balance sheet.